New Jersey biotech plans for tiny IPO; Vir gets $10M Gates Foundation grant for HIV vaccine
Chromocell Therapeutics, based in North Brunswick, New Jersey, plans to go public, according to an SEC filing.
According to its LinkedIn, Chromocell works in drug discovery as well as flavor development. Years ago, the biotech licensed out a pain candidate to Astellas for $15 million upfront. — Lei Lei Wu
This section was corrected to remove an inaccurate reference to the SEC filing of how much Chromocell will raise from its IPO.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.